A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
Market Scope
Trusted Global Partner of Industry and Medical Professionals for Ophthalmic Market Research, Primary Research, Independent Perspective, & Objective Analysis
Choose Your Experience
Over 500 Clients, Large & Small from Around the World, Trust Market Scope Data & Analysis
Latest Market Reports
Market Scope's industry reports are meticulously prepared by a dedicated team of in-house consultants/analysts with over 100 years of collective experience.
- 378
Comprehensive Pages
- 35
Competitors Profiled
- 11
IOL Categories Forecasted
- 8
Geographic and Economic Breakouts
2025 IOL Market Report: Global Analysis for 2024 to 2030, March, 2025
The “2025 IOL Market Report” provides an in-depth analysis of the current intraocular lens market and forecasts performance over the next five years. It includes analysis of current markets, identification of important trends, and discussion of key factors for future success.
This report describes and forecasts performance by region for 12 categories of IOLs: commodity monofocal, enhanced monofocal, intermediate-optimized monofocal, toric, PC-toric, bifocal, trifocal, extended depth of focus (EDOF), EDOF multifocal hybrid, accommodating, post-op adjustable, and phakic IOLs. Additionally, 35 companies are profiled, with discussion of their products, strategic market position, background, and outlook.
Latest Industry News & Trends
1/30/2026
BreakingGlaucomaRegulation
US FDA Approves Re-administration of Glaukos’ iDose TR
Glaukos announced Jan. 28 that the US FDA had approved a supplement to its new drug application allowing for re-administration of iDose TR, the company’s intracameral travoprost implant for glaucom...
1/30/2026
BreakingFundingPresbyopiaRegulation
US FDA Approves Tenpoint’s Yuvezzi Drops for Presbyopia
Tenpoint Therapeutics announced Jan. 28 that the US FDA had approved Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution 2.75%/0.1%) for presbyopia. The company said it expects to launc...
1/30/2026
BreakingDeviceEuropeIndiaPharmaRegulation
EU-India Free Trade Agreement to Phase in Lower Pharma and Device Tariffs
A free trade agreement reached Jan. 27 by the European Union and India will reduce or eliminate tariffs on about 90 percent of goods, including pharmaceuticals and medical devices, between the two ...
1/30/2026
BreakingPharmaRegulation
US FDA Rolls Out PreCheck Program to Speed Approval of Drug Manufacturing Plants
The US FDA announced Jan. 21 that it would begin accepting applications on Feb. 1, 2026, for its new PreCheck Pilot Program to improve the regulatory process for US manufacturing facilities. The ag...
1/30/2026
BreakingDiagnosticEquipmentRefractive
Nidek launches the Phantom Open-Field Refraction System
Japanese company Nidek reported Jan. 26 that it had launched the Phantom Open-Field Refractive System. An open-field system eliminates the traditional phoropter in front of the patient; instead, vi...
1/30/2026
BreakingClinical TrialRegulationUveitis
US FDA Gives Green Light to Phase II Trial of Novaliq’s Topical Uveitis Candidate
Germany’s Novaliq reported on Jan. 26 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase II trial of NOV05, its topical, ...
1/30/2026
BreakingClinical TrialCornealRegulation
US FDA Authorizes Compassionate Use of Urcosimod for Neuropathic Corneal Pain
London’s Okyo Pharma announced Jan. 23 that the US FDA had authorized a compassionate-use request for a single patient with severe neuropathic corneal pain to be treated with urcosimod (0.05%). The...
1/30/2026
BreakingCornealIndustryRetina
Emmecell Appoints Ramin Valian as Chief Executive Officer
Emmecell announced Jan. 16 that it had appointed ophthalmic industry veteran Ramin Valian as chief executive officer. Valian spent more than 20 years in top roles at Allergan and AbbVie, where he d...
Provider Surveys & Interviews
Grab a seat at the table and join the thousands of ophthalmologists and optometrists from over 60 countries who are helping shape the next generation of diagnostics, pharmaceuticals, devices, and equipment by sharing your opinion and experience. Make your voice heard!
Choose Your Own Adventure
Participation options include weekly polls, special sponsored surveys, syndicated quarterly surveys, focus groups, and interviews, each with varying levels of honoraria.
Safe, Secure & On Any Device
We follow all industry standards to ensure confidentiality between participants and clients. Start and stop surveys anytime on our free Market Scope+ App or on desktop, each with a personalized dashboard just for you.
Pre-Qualified Invitations
We individually verify all potential participants before each survey or interview, ensuring that only licensed eye care professionals are invited and they are never kicked out or disqualified.
Better Data = Better Decisions
A team of industry experts and analysts review each data point, so you can be confident in the results and trends provided in our reports.
Download the Market Scope+ app to get started!
Market Scope Methodology
A Multi-Step Approach for Accurate & Timely Data
Proprietary data
- 20+ years of physician survey data
- Disease models
- Cultivated database of physicians, ASCs, and hospitals
- Insight from our team of in-house industry experts
Public data
- Attendance and participation at major, worldwide meetings
- Public health systems and registries
- Clinical study data
- Analysis of company-published financial reports
Join Market Scope Today
Register A Corporate Account
Register A Clinical Account
A clinical account gives you access to survey participation and results, weekly polls, benchmark reports, a searchable news archive, and more on a personalized dashboard.